Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’
Be Bio uses Arch Venture-led $130M financing round to harness [...]
Editas brings on Sarepta CMO—for CEO swap, not the vacant CMO role
Editas brings on Sarepta CMO—for CEO swap, not the vacant [...]
ProQR slashes 30% of workforce following phase 2/3 blunder
ProQR slashes 30% of workforce following phase 2/3 blunder mbayer [...]
Cardiff Oncology’s chief medical officer exits after less than a year
Cardiff Oncology’s chief medical officer exits after less than a [...]
Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic
Swiss biotech CDR Life uses $76M series A funding round [...]
AACR: AbbVie’s navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark
AACR: AbbVie’s navitoclax goes after tough blood cancer, not yet [...]
Carlyle’s acquisition of Abingworth brings $2 billion to fuel life science investments
Carlyle’s acquisition of Abingworth brings $2 billion to fuel life [...]
Aeglea’s search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%
Aeglea’s search for signs of efficacy in phase 3 rare [...]
Gilead’s CD47 trials freed of FDA hold—for the most part
Gilead’s CD47 trials freed of FDA hold—for the most part [...]
Liver enzyme might hold the secret to new obesity treatments
Liver enzyme might hold the secret to new obesity treatments [...]